Bicara Therapeutics Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Sep 2025 | Jun 2025 | Mar 2025 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-55.4M | $-56.2M | $-36.3M | $-27.4M | $-36.8M | $-17.5M | $-17.0M | $-12.5M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | — | $44.0K | — | — | $19.0K | — | — | $13.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | $5.9M | — | — | $3.5M | — | — | $1.1M |
| Net Cash from Operating Activities | $-44.2M | $-37.5M | $-29.2M | $-25.6M | $-28.1M | $-17.2M | $-12.9M | $-14.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $60.0K | $60.0K | $42.0K | $0 | $0 | $8.0K | $19.0K | $4.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | — | $100.9M | — | — | $0 | — | — | $58.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | — | $163.3M | — | — | $460.0K | — | — | $137.0K |
| Net Change in Cash | — | $226.8M | — | — | $-27.6M | — | — | $-14.4M |
| Free Cash Flow | $-44.3M | $-37.6M | $-29.3M | $-25.6M | $-28.1M | $-17.2M | $-12.9M | $-14.6M |